Legal Advantage Investments Inc. Buys 11,000 Shares of GRAIL, Inc. $GRAL

Legal Advantage Investments Inc. raised its stake in GRAIL, Inc. (NASDAQ:GRAL) by 32.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,500 shares of the company’s stock after purchasing an additional 11,000 shares during the period. Legal Advantage Investments Inc.’s holdings in GRAIL were worth $2,300,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Rockefeller Capital Management L.P. lifted its stake in shares of GRAIL by 18.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 68,577 shares of the company’s stock worth $5,870,000 after buying an additional 10,565 shares during the last quarter. Osbon Capital Management LLC acquired a new position in GRAIL in the 4th quarter valued at about $51,000. Fund Advisors of America Inc FL bought a new position in GRAIL in the 4th quarter valued at about $299,000. DUTCH ASSET Corp bought a new position in GRAIL in the 4th quarter valued at about $532,000. Finally, Corient Private Wealth LLC lifted its position in GRAIL by 60.4% during the fourth quarter. Corient Private Wealth LLC now owns 9,274 shares of the company’s stock worth $794,000 after acquiring an additional 3,491 shares during the last quarter.

GRAIL Stock Down 1.6%

Shares of GRAIL stock opened at $61.11 on Wednesday. GRAIL, Inc. has a 12-month low of $29.95 and a 12-month high of $118.84. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of -5.89 and a beta of 3.15. The firm’s 50-day moving average price is $59.70 and its two-hundred day moving average price is $72.14.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The company had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. On average, sell-side analysts expect that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Insider Activity

In other GRAIL news, CFO Aaron Freidin sold 45,806 shares of the company’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the sale, the chief financial officer directly owned 260,669 shares in the company, valued at $13,012,596.48. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 232,464 shares of company stock valued at $11,621,242. 1.83% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on GRAL shares. Morgan Stanley reduced their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Piper Sandler lifted their price target on GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Robert W. Baird set a $70.00 price target on GRAIL in a research note on Wednesday, May 6th. The Goldman Sachs Group began coverage on GRAIL in a research note on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company. Finally, Mizuho assumed coverage on GRAIL in a research report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $67.00.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Glancy Prongay, and others, issued reminders that investors who bought GRAL between May 13, 2025 and February 19, 2026 may join the securities fraud class action, with an August 4, 2026 lead-plaintiff deadline. Article Title
• Neutral Sentiment: The lawsuits allege GRAIL misled investors about its NHS-Galleri trial results, and one filing says the February 20 trial update erased more than $2.2 billion in market value, underscoring the magnitude of the alleged disclosure issue. Article Title
• Negative Sentiment: The mounting legal announcements add to investor uncertainty and could weigh on sentiment toward GRAIL as shareholders await further developments in the class action process. Article Title

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.